J. Egger

发表

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

T. Ciuleanu, M. Rodríguez-Torres, I. Bondarenko, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas

M. Ladanyi, C. Rudin, M. Kris, 2022, medRxiv.

METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

M. Gounder, D. Rasco, L. Siu, 2019, Annals of Oncology.

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

T. Ciuleanu, G. Aktan, I. Bondarenko, 2014 .